A phase 2 study to evaluate the novel combination of Carrick's samuraciclib (CT7001) and Menariniis oral selective estrogen receptor degrader (SERD), elacestrant, in patients with CDK4/6i resistant HR+, HER2- metastatic breast cancer
Latest Information Update: 22 Dec 2022
At a glance
- Drugs Elacestrant (Primary) ; Samuraciclib (Primary)
- Indications Advanced breast cancer; HER2 negative breast cancer
- Focus Therapeutic Use
- Sponsors Carrick Therapeutics; Menarini
Most Recent Events
- 22 Dec 2022 New trial record
- 19 Dec 2022 According to a Menarini media release, Carrick anticipates initiating this clinical trial in 2023.
- 19 Dec 2022 According to a Menarini media release, Carrick Therapeutics and The Menarini Group Announce Clinical Trial Collaboration to execute this trial.